Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

This study has been completed.
Information provided by:
International Partnership for Microbicides, Inc. Identifier:
First received: March 15, 2006
Last updated: July 28, 2006
Last verified: July 2006

March 15, 2006
July 28, 2006
October 2005
Not Provided
Local and systemic safety and tolerability.
Same as current
Complete list of historical versions of study NCT00303576 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.
Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel. The volunteers will receive investigational product for a total of 42 days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and compliance.
Not Provided
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
HIV Infections
Drug: dapivirine (TMC120) vaginal gel
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2006
Not Provided

Inclusion Criteria:

  • HIV-negative
  • Willing to participate and sign an informed consent
  • Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group.
  • Willing to use two forms of contraception during the study.
  • Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study.
  • Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses.
  • Willing to abstain from using any vaginal product (other than the study product or placebo).
  • Willing to be sexually abstinent from randomization until completion of Day 7 evaluations.

Exclusion Criteria:

  • Currently pregnant or breast-feeding.
  • Clinically detectable genital abnormality on the vulva, vaginal walls or cervix.
  • Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions.
  • Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization.
  • Symptomatic bacterial vaginosis and unwilling to undergo treatment.
  • Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Rwanda,   South Africa,   Tanzania
Not Provided
Not Provided
Not Provided
Not Provided
International Partnership for Microbicides, Inc.
Not Provided
Study Director: Zeda Rosenberg, ScD IPM
International Partnership for Microbicides, Inc.
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP